hotspot -WSS

hotspot

author：entertainment 2025-08-19 18:07:05 - browse：2262

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： WuXi out of biotech trade group, U.S. and China relations to blame

WSS

Why depression after traumatic brain injury is distinct

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Pharma companies must ensure equitable access to obesity drugs

As AI in medicine takes off, can 'human in the loop' prevent harm?

How many hemophilia patients actually want gene therapy?

NIH tests clinical research in primary care with $30 million program

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

At least 13 dead in Texas as scorching temps continue

Pushing for an NIH office for post

Malaria cases in Florida and Texas: Here’s what you need to know

Readers discuss the intersection of pregnancy and addiction

Dobbs anniversary: the lost opportunity of abortion as health care

Moderna says combo Covid

Sports medicine is finally prioritizing gender equality

Health care court cases: Humana, Sutter, Novant

Virginia high school admissions case could be legal follow

Medical device trials still don't enroll enough women, study finds

explore

Pushing for an NIH office for post

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

How many hemophilia patients actually want gene therapy?

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

FDA advisers back CAR

Report captures long Covid’s disabling effects and policy challenges

hotspot

explore

focus

focus